Printer Friendly

DiagnoCure Inc. is Listing Today on The Montreal Exchange.

MONTREAL--(BUSINESS WIRE)--Nov. 26, 1996--DIAGNOCURE(ME CUR. CUR.WT.) DiagnoCure Inc. of Sainte-Foy (Quebec) is listing today on The Montreal Exchange, following an Initial Public Offering. The company is listing 22,879,774 common shares, of which 17,218,832 are issued and outstanding, and 4,125,000 warrants, of which 3,750,000 are issued and outstanding. Each warrant allows its holder to buy one common share of DiagnoCure at a price of $6.00 before May 25, 1998.

Founded in 1994, DiagnoCure Inc. is a biopharmaceutical company specialized in the development and commercialization of products for the diagnosis and treatment of genito-urinary cancers (bladder, prostate, kidney) and breast cancers.

Net proceeds of the Initial Public Offering amounted to approximately $13.5 million and will be used principally to fund research and development programmes, including sensitive immunodetection products resulting in earlier diagnosis, staging products, chemotherapy or radiotherapy products targeted to tumors and therapeutic vaccines.

In Canada, DiagnoCure operates a reference laboratory and has its own salesforce. Internationally, the Company is establishing alliances and licences to commercialize its technologies and products. "We believe that our products will be vital elements in the implementation of cost-effective treatment programmes and the containment of medical costs" said Serge Pitre, President and Chief Executive Officer of DiagnoCure Inc.

The head office of DiagnoCure Inc. is located at 2050 Rene-Levesque Boul. West, 6th floor, Ste-Foy (Quebec) G1V 2K8.

CONTACT: DiagnoCure Inc.

Serge Pitre, 418/ 527-6100
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 26, 1996
Words:241
Previous Article:Certification complete for ANSYS availability on Intergraph platform.
Next Article:NVID prepares to bring Microsafe into production in early 1997 for veterinarian uses.
Topics:


Related Articles
IDB to Consolidate Stock Exchange Listings.
RE:DiagnoCure Inc. Filed a Preliminary Prospectus.
RE: DiagnoCure Inc. Announces That it Has Filed a Final Prospectus Relating to an Initial Public Offering of Units.
DiagnoCure Inc. -- first six months results.
DiagnoCure - Major Technology Transfer in Molecular Biology.
DiagnoCure Inc. Announces Third Quarter and Nine-Month Results.
DiagnoCure Inc. -- Second Quarter Highlights and Results -- First Recipient of the Friesen-Rygiel Price Launched by the Canadian Medical Discoveries...
DiagnoCure Inc. - Two Highly Reputed Specialists Join Scientific Advisory Committe.
DiagnoCure Enters Into Exclusive Agreement With Microtech of France for the Distribution of its Immunocyt Test in France and in Parts of Africa.
GEN-PROBE ACQUIRES DIAGNOSTIC RIGHTS TO PROSTATE CANCER GENE.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters